Parameters | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
LRR (n = 38) | No LRR (n = 394) | P value | Odds ratio | 95% confidence interval | P value | |
Age (years) | 0.661 | |||||
≦50 | 25 (9.3%) | 245 (90.7%) | ||||
> 50 | 13 (8.0%) | 149 (92.0%) | ||||
Clinical T stage | 0.77 | |||||
T1 | 2 (8.0%) | 23 (92.0%) | ||||
T2 | 28 (8.5%) | 302 (91.5%) | ||||
T3 | 7 (12.1%) | 51 (87.9%) | ||||
T4 | 1 (5.3%) | 18 (94.7%) | ||||
Clinical lymph node status | 0.089 | |||||
N0 | 1 (1.7%) | 57 (98.3%) | ||||
N1 | 24 (9.1%) | 239 (90.9%) | ||||
N2 | 13 (11.7%) | 98 (88.3%) | ||||
SBR grade | 0.091 | |||||
1 | 1 (3.3%) | 29 (96.7%) | ||||
2 | 13 (8.0%) | 150 (92.0%) | ||||
3 | 23 (12.0%) | 168 (88.0%) | ||||
Unknown | 1 (2.1%) | 47 (97.9%) | ||||
Histologic type | 0.127 | |||||
Invasive ductal carcinoma | 36 (8.5%) | 389 (91.5%) | ||||
Invasive lobular carcinoma | 1 (25.0%) | 3 (75.0%) | ||||
Mucinous carcinoma | 0 | 1 (100.0%) | ||||
Others | 1 (50.0%) | 1 (50.0%) | ||||
Margin | > 0.999 | |||||
Free | 36 (8.8) | 371 (91.2%) | ||||
Positive | 2 (8.0%) | 23 (92.0%) | ||||
ER | 0.005 | |||||
Positive | 14 (5.6%) | 238 (94.4%) | ||||
Negative | 24 (13.3%) | 156 (86.7%) | ||||
PR | 0.004 | |||||
Positive | 9 (4.5%) | 190 (95.5%) | ||||
Negative | 29 (12.4%) | 204 (87.6%) | ||||
HER2 | 0.151 | |||||
Positive | 21 (11.0%) | 170 (89.0%) | ||||
Negative | 17 (7.1%) | 224 (92.9%) | ||||
Subtype | 0.029 | |||||
HR + /HER2− | 7 (4.6%) | 146 (95.4%) | 1 | |||
HR + /HER2 + | 8 (7.5%) | 99 (92.5%) | 1.685 | 0.592–4.797 | 0.328 | |
HR-/HER2 + | 13 (15.5%) | 71 (84.5%) | 3.819 | 1.460–9.990 | 0.006 | |
HR−/HER2− | 10 (11.4%) | 78 (88.6%) | 2.674 | 0.980–7.300 | 0.055 | |
Neoadjuvant regimens | 0.345 | |||||
Anthracycline only | 2 (18.2%) | 9 (81.8%) | ||||
Taxane only | 1 (2.6%) | 37 (97.4%) | ||||
Anthracycline + taxane | 19 (8.5%) | 204 (91.5%) | ||||
Chemotherapy + target therapy | 16 (10.0%) | 144 (90.0%) | ||||
pCR | 0.111 | |||||
Yes | 8 (5.7%) | 133 (94.3%) | ||||
No | 30 (10.3%) | 261 (89.7%) |